Such consistent findings indicated that the hypermethylation status of HOX genes could be exploited not only to monitor EGFR-TKI resistance in NSCLC patients, but also to predict and treat MET or HER2 amplification mediated resistance (56). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.